Literature DB >> 7521165

Neurotensin receptor and its mRNA are expressed in many human colon cancer cell lines but not in normal colonic epithelium: binding studies and RT-PCR experiments.

J J Maoret1, D Pospaï, C Rouyer-Fessard, A Couvineau, C Laboisse, T Voisin, M Laburthe.   

Abstract

Neurotensin receptor expression was studied in 19 human colon cancer cell lines and normal human colon by i) binding experiments using [125I-Tyr3]-neurotensin; ii) RT-PCR analysis. The following data were obtained: 1) A single class of receptor (Kd ranging from 0.23 to 1.21 nM) was found in 9 out of 19 cell lines but not in normal colonic epithelium; 2) The Bmax was in the range between 1000 and 85 fmoles/mg protein with SW48 > WiDR > Cl 19A > HCT116 > SW480 > SW620 > Cl 16E > Cl 27H > HT-29. No specific binding was measurable in Caco-2, FRI, CBS, EB, HCT-8, 320HRS, 320DM and LS174T cell lines; 3) A single RT-PCR product was observed in HT-29, SW48, WIDR, Cl 19A, SW480, Cl 16E, Cl 27H, SW620 and HCT116, but not in other cell lines or in normal human colon. It is concluded that the expression of neurotensin receptors in human colon cancer cells is regulated at the mRNA level and occurs upon malignancy in > 40% of colon cancer cell lines.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7521165     DOI: 10.1006/bbrc.1994.2205

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  22 in total

1.  Modifications at Arg and Ile Give Neurotensin(8-13) Derivatives with High Stability and Retained NTS1 Receptor Affinity.

Authors:  Lisa Schindler; Günther Bernhardt; Max Keller
Journal:  ACS Med Chem Lett       Date:  2019-05-10       Impact factor: 4.345

Review 2.  The orexin receptor OX(1)R in colon cancer: a promising therapeutic target and a new paradigm in G protein-coupled receptor signalling through ITIMs.

Authors:  Marc Laburthe; Thierry Voisin
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

3.  Neurotensin phosphorylates GSK-3alpha/beta through the activation of PKC in human colon cancer cells.

Authors:  Qingding Wang; Yuning Zhou; B Mark Evers
Journal:  Neoplasia       Date:  2006-09       Impact factor: 5.715

4.  Gut peptide receptor expression in human pancreatic cancers.

Authors:  R A Ehlers; Sh Kim; Y Zhang; R T Ethridge; C Murrilo; M R Hellmich; D B Evans; C M Townsend; B Mark Evers
Journal:  Ann Surg       Date:  2000-06       Impact factor: 12.969

5.  Exploratory Analysis of Plasma Neurotensin as a Novel Biomarker for Early Detection of Colorectal Polyp and Cancer.

Authors:  Shengyang Qiu; Stella Nikolaou; Francesca Fiorentino; Shahnawaz Rasheed; Ara Darzi; David Cunningham; Paris Tekkis; Christos Kontovounisios
Journal:  Horm Cancer       Date:  2019-05-15       Impact factor: 3.869

6.  Neurotensin is a proinflammatory neuropeptide in colonic inflammation.

Authors:  I Castagliuolo; C C Wang; L Valenick; A Pasha; S Nikulasson; R E Carraway; C Pothoulakis
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

7.  Suppression of neurotensin receptor type 1 expression and function by histone deacetylase inhibitors in human colorectal cancers.

Authors:  Xiaofu Wang; Lindsey N Jackson; Sara M Johnson; Qingding Wang; B Mark Evers
Journal:  Mol Cancer Ther       Date:  2010-07-27       Impact factor: 6.261

8.  Phospholipase C and src tyrosine kinases mediate neurotensin-stimulated Cl- secretion in rabbit proximal colon.

Authors:  Roli Prasad; Jayashree Venkatasubramanian; Milen Amde; Mrinalini Chatta Rao
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

9.  [99mTc]Demotensin 5 and 6 in the NTS1-R-targeted imaging of tumours: synthesis and preclinical results.

Authors:  Theodosia Maina; Anastasia Nikolopoulou; Eleni Stathopoulou; Athanassios S Galanis; Paul Cordopatis; Berthold A Nock
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06-27       Impact factor: 9.236

10.  Growth-promoting effect of muscarinic acetylcholine receptors in colon cancer cells.

Authors:  J-I Ukegawa; Y Takeuchi; S Kusayanagi; K Mitamura
Journal:  J Cancer Res Clin Oncol       Date:  2003-05-14       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.